Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Exviera dasabuvir: Phase IIIb data

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Exviera dasabuvir (ABT-333) Business: Infectious Molecular target: HCV NS5B polymerase Description: Non-nucleoside HCV NS5B polymerase inhibitor Indication: Treat chronic …

    Published on 8/17/2015
  • Filgotinib: Phase IIb final data

    Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), Mechelen, Belgium AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Filgotinib (GLPG0634) Business: Autoimmune Molecular target: Janus kinase-1 (JAK-1) Description: Janus …

    Published on 8/17/2015
  • GSK2315698: Phase I data

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: GSK2315698 Business: Endocrine/Metabolic Molecular target: Serum amyloid P component (SAP) (APCS) Description: (R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-…

    Published on 8/17/2015
  • GSK2398852: Phase I data

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: GSK2398852 Business: Endocrine/Metabolic Molecular target: Serum amyloid P component (SAP) (APCS) Description: Humanized monoclonal IgG1 anti-serum amyloid …

    Published on 8/17/2015
  • HPBCD: Preliminary Phase I data

    Vtesse Inc., Gaithersburg, Md. Product: HPBCD (VTS-270) 2-hydroxypropyl-b-cyclodextrin Business: Endocrine/Metabolic Molecular target: NA Description: 2-hydroxypropyl-b-cyclodextrin targeting cholesterol and …

    Published on 8/17/2015
  • Human plasma-derived plasminogen: Phase I data

    ProMetic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF), Laval, Quebec Product: Human plasma-derived plasminogen Business: Hematology Molecular target: NA Description: Human plasma-derived purified plasminogen formulated for…

    Published on 8/17/2015
  • Multi-Gene Hereditary Cancer Test: Clinical trial data

    Invitae Corp. (NYSE:NVTA), San Francisco, Calif. Product: Multi-Gene Hereditary Cancer Test, Hereditary Cancer Syndromes Test Business: Diagnostic Molecular target: NA Description: Next-generation sequencing (NGS)-based…

    Published on 8/17/2015
  • Nuedexta dextromethorphan/quinidine: Phase IV data

    Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Product: Nuedexta dextromethorphan/quinidine (AVP-923) (formerly Neurodex) Business: Neurology Molecular target: NMDA receptor; Sigma-1 receptor Description: Combination of …

    Published on 8/17/2015
  • Ombitasvir/paritaprevir/ritonavir: Phase IIIb data

    Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), Watertown, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Ombitasvir/paritaprevir/ritonavir (Viekirax, Technivie) Business: Infectious Molecular target: HCV NS3/4A …

    Published on 8/17/2015
  • Oxycodone: Clinical trial data

    Egalet Corp. (NASDAQ:EGLT), Wayne, Pa. Product: Oxycodone (Egalet-002) (formerly EG-P114) Business: Neurology Molecular target: Opioid receptor (OPR) Description: Abuse-deterrent, extended-release, oral formulation of …

    Published on 8/17/2015
  • Oxycodone: Clinical trial data

    Egalet Corp. (NASDAQ:EGLT), Wayne, Pa. Product: Oxycodone (Egalet-002) (formerly EG-P114) Business: Neurology Molecular target: Opioid receptor (OPR) Description: Abuse-deterrent, extended-release, oral formulation of …

    Published on 8/17/2015
  • Oxycodone: Clinical trial data

    Egalet Corp. (NASDAQ:EGLT), Wayne, Pa. Product: Oxycodone (Egalet-002) (formerly EG-P114) Business: Neurology Molecular target: Opioid receptor (OPR) Description: Abuse-deterrent, extended-release, oral formulation of …

    Published on 8/17/2015
  • Pimavanserin: Phase III data

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), San Diego, Calif. Product: Pimavanserin (Nuplazid) (formerly ACP-103) Business: Neurology Molecular target: Serotonin (5-HT2A) receptor Description: Small molecule serotonin (5…

    Published on 8/17/2015
  • RSV F vaccine: Phase II data

    Novavax Inc. (NASDAQ:NVAX), Gaithersburg, Md. Product: RSV F vaccine Business: Infectious Molecular target: RSV F protein Description: Respiratory syncytial virus (RSV) vaccine targeting RSV viral fusion F protein …

    Published on 8/17/2015
  • Selinexor: Phase II data

    Karyopharm Therapeutics Inc. (NASDAQ:KPTI), Natick, Mass. Product: Selinexor (KPT-330) Business: Cancer Molecular target: Exportin 1 (XPO1) (CRM1) Description: Oral selective inhibitor of nuclear export (SINE) protein …

    Published on 8/17/2015
  • Tenofovir alafenamide fumarate: Phase III data

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: Tenofovir alafenamide fumarate (TAF)/elvitegravir/cobicistat/emtricitabine (formerly GS-7340/elvitegravir/cobicistat/emtricitabine) Business: Infectious …

    Published on 8/17/2015
  • ThermoDox heat-activated liposome: Additional Phase III data

    Celsion Corp. (NASDAQ:CLSN), Lawrenceville, N.J. Yakult Honsha Co. Ltd. (Tokyo:2267), Tokyo, Japan Zhejiang Hisun Pharmaceutical Co. Ltd. (Shanghai:600267), Taizhou City, China Product: ThermoDox heat-activated liposome…

    Published on 8/17/2015
  • Venetoclax: Phase II data

    Genentech Inc., South San Francisco, Calif. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Venetoclax (ABT-199, RG7601) (formerly GDC-0199) Business: Cancer Molecular …

    Published on 8/17/2015
  • Vigabatrin: Phase I/II data

    Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), Coral Gables, Fla. Product: Vigabatrin (CPP-109) Business: Neurology Molecular target: GABA transaminase Description: Irreversible inhibitor of GABA transaminase Indication: …

    Published on 8/17/2015
  • Xilonix: Phase III data

    XBiotech Inc. (NASDAQ:XBIT), Austin, Texas Product: Xilonix (MABp1) (CV-18C3, T2-18C3, RA-18C3, CA-18C3) Business: Cancer Molecular target: Interleukin-1 (IL-1) alpha Description: Human mAb against IL-1 alpha Indication…

    Published on 8/17/2015
  • ADAP NY-ESO TCR: Additional Phase I/II data

    Adaptimmune Therapeutics plc (NASDAQ:ADAP), Abingdon, U.K. Product: ADAP NY-ESO TCR (formerly Enhanced TCR therapy targeting NY-ESO-1) Business: Cancer Molecular target: Cancer/testis antigen 1B (CTAG1B) (NY-ESO-1) …

    Published on 8/3/2015
  • Bempedoic acid: Phase II data

    Esperion Therapeutics Inc. (NASDAQ:ESPR), Ann Arbor, Mich. Product: Bempedoic acid (ETC-1002) Business: Endocrine/Metabolic Molecular target: ATP citrate lyase (ACLY) Description: ATP citrate lyase (ACLY) inhibitor …

    Published on 8/3/2015
  • Bioabsorbable Cardiac Matrix: Phase II data

    Bellerophon Therapeutics Inc. (NASDAQ:BLPH), Hampton, N.J. BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Jerusalem, Israel Product: Bioabsorbable Cardiac Matrix (BCM) device (BL-1040, IK-5001) Business: Cardiovascular …

    Published on 8/3/2015
  • Blincyto blinatumomab: Phase II data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Blincyto blinatumomab (AMG 103) (formerly MT103) Business: Cancer Molecular target: CD19 Description: Bispecific T…

    Published on 8/3/2015
  • BMS-955176: Additional Phase IIa data

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: BMS-955176 Business: Infectious Molecular target: NA Description: Second generation HIV-1 maturation inhibitor Indication: Treat HIV-1 infection Endpoint: …

    Published on 8/3/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993